Special presentation
Immunosuppression After Pancreas Transplantation

https://doi.org/10.1016/j.transproceed.2005.03.155Get rights and content

First page preview

First page preview
Click to open first page preview

References (16)

  • D.B. Kaufman

    Immunosuppression in pancreas transplantationinduction therapy

  • A.C. Gruessner et al.

    Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of May 2003

  • R.W.G. Gruessner

    Maintenance therapy

  • R.W.G. Gruessner

    Immunobiology, diagnosis, and treatment of pancreas graft rejection

  • Proceedings of the 2nd International Congress on Immunosuppression

    Transplant Proc

    (2002)
  • W.O. Bechstein et al.

    Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation1-year results of a large multicenter trial

    Transplantation

    (2004)
  • G.W. Burke et al.

    Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantationthree-year results

    Transplantation

    (2004)
  • R.J. Stratta et al.

    Two-dose alemtuzumab regimen in simultaneous kidney-pancreas transplant recipientsprimary endpoint analysis of a multicenter, randomized study

    Transplantation

    (2003)
There are more references available in the full text version of this article.

Cited by (6)

  • Comprehensive immune monitoring reveals profound immunological changes in pancreas after kidney (PAK) transplant recipients

    2013, Human Immunology
    Citation Excerpt :

    PT remains the treatment of choice in T1DM patients with complex disease that may or may not be associated with end-stage renal failure. While advances in the pre-operative and post-operative phases have dramatically improved graft survival for all types of PT [18], there is a historical precedent for inferior outcomes in PAK compared to SPK due to immunological failure to maintain the graft [19]. As a result, the dose of induction therapy is increased in PT [20], whether they are T-cell-depleting (ATG), or non-depleting (OKT3, anti-CD25 monoclonals).

  • Pancreas and Islet transplantation in diabetes

    2008, Journal of the Korean Medical Association
View full text